LSDIF (Lucy Scientific Discovery) LT-Debt-to-Total-Asset: 0.17 (As of Dec. 2023)


What is Lucy Scientific Discovery LT-Debt-to-Total-Asset?

Lucy Scientific Discovery LSDIF LT-Debt-to-Total-Asset is 0.17 as of Dec. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lucy Scientific Discovery's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.17.

Lucy Scientific Discovery's long-term debt to total assets ratio declined from Dec. 2022 (0.59) to Dec. 2023 (0.17). It may suggest that Lucy Scientific Discovery is progressively becoming less dependent on debt to grow their business.

Lucy Scientific Discovery  (OTCPK:LSDIF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lucy Scientific Discovery LT-Debt-to-Total-Asset Related Terms

Lucy Scientific Discovery LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucy Scientific Discovery LT-Debt-to-Total-Asset Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
LT-Debt-to-Total-Asset
0.17 0.78 0.16

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.59 0.15 0.16 0.21 0.17

Lucy Scientific Discovery LT-Debt-to-Total-Asset Calculation

Lucy Scientific Discovery's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )/Total Assets (A: Jun. 2023 )
=1.39/8.779
=0.16

Lucy Scientific Discovery's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.719/4.287
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.17 mean?
Lucy Scientific Discovery (LSDIF) has a LT-Debt-to-Total-Asset of 0.17 as of Dec. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lucy Scientific Discovery and its competitors.
Is Lucy Scientific Discovery's LT-Debt-to-Total-Asset too high?
Lucy Scientific Discovery's current LT-Debt-to-Total-Asset is 0.17.
How does Lucy Scientific Discovery's LT-Debt-to-Total-Asset compare to INQD and ZTS?
Lucy Scientific Discovery's LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lucy Scientific Discovery and its competitors. Lucy Scientific Discovery's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current LT-Debt-to-Total-Asset of 0.17. The current LT-Debt-to-Total-Asset is 0.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current LT-Debt-to-Total-Asset is 0.17 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.